All In Biotech

Drug Trial Radar · NCT05133531

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Aug 1, 2022

Primary completion

Sep 28, 2026

Study completion Oct 29, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab. The pozelimab + cemdisiran combination may be referred to as "study drugs". Ravulizumab and eculizumab may also be called the "comparator drug". The study is looking at several research questions, including: * How effective is the pozelimab + cemdisiran combination compared to ravulizumab? * How effective is pozelimab + cemdisiran combination compared to eculizumab? * What side effects may happen from taking the study drugs? * How much study drugs are in the blood at different times? * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • RavulizumabDrug

    Administered Intravenous (IV) per the protocol

  • PozelimabDrug

    Administered IV and subcutaneous (SC) per the protocol

  • CemdisiranDrug

    Administered SC per the protocol

  • EculizumabDrug

    Administered IV per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in lactate dehydrogenase (LDH)Time frame: From baseline to week 26
  2. Transfusion avoidanceTime frame: From post-baseline day 1 through week 26
  3. Adequate control of hemolysisTime frame: From week 8 through week 26, inclusive

Locations

68 sites in 24 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope & Innovation

    Whittier, California

  • A Beneficencia Portuguesa de Sao Paulo, BP Mirante

    São Paulo, Brazil

  • Casa de Saude Santa Marcelina

    São Paulo, Brazil

  • Centro de Estudos e Pesquisas em Hematologia e Oncologia

    Santo André, São Paulo, Brazil

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Hospital Pablo Tobon Uribe

    Medellín, Antioquia, Colombia

  • George Papanikolaou Hospital

    Thessaloniki, Greece

  • Semmelweis University

    Budapest, Hungary

  • Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC)

    Jaipur, India

  • Malabar Cancer Center, Kerala

    Kannur, Kerala, India

  • Amrita Institute of Medical Sciences (AIMS) and Research Centre Aims

    Kochi, Kerala, India

  • K J Somaiya Super Specialty Hospital & Research Centre

    Mumbai, Maharashtra, India

  • Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus

    New Delhi, National Capital Territory of Delhi, India

  • Postgraduate Institute of Medical Education & Research (PGIMER)

    Chandigarh, Punjab, India

  • King George Hospital

    Lucknow, Uttar Pradesh, India

  • Sanjay Gandhi Postgraduate Institute of Medical Sciences

    Lucknow, Uttar Pradesh, India

  • Hematology Citta della Salute e della Scienza di Torino

    Turin, Italy

  • Aou Careggi

    Florence, Firenze, Italy

  • Fondazione Policlinico Universitario A. Gemelli - IRCCS

    Rome, Roma, Italy

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan

  • Ogaki Municipal Hospital

    Ōgaki, Gifu, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan

  • Matsushita Memorial Hospital

    Moriguchi, Osaka, Japan

  • NTT Medical Center Tokyo

    Shinagawa-ku, Tokyo, Japan

  • Jordan University Hospital (JUH)

    Amman, Jordan

  • Hospital Tg Ampuan Afzan

    Kuantan, Pahang, Malaysia

  • Hospital Queen Elizabeth

    Kota Kinabalu, Sabah, Malaysia

  • Hospital Ampang

    Ampang, Selangor, Malaysia

  • Servicio de Hematologia del Hospital Universitario de la Uanl

    Monterrey, Nuevo León, Mexico

  • Clinica San Felipe

    Lima, Peru

  • St Lukes Medical Center

    Quezon, Central Luzon, Philippines

  • Szpital Uniwersytecki Nr2 Bydgoszcz

    Bydgoszcz, Poland

  • Institute of Hematology and Transfusion Medicine

    Warsaw, Poland

  • University Clinical Center Medical University of Gdansk

    Gdansk, Pomeranian Voivodeship, Poland

  • Ion Chiricuta Oncology Institute

    Cluj-Napoca, Cluj, Romania

  • Municipal Hospital Filantropia

    Craiova, Dolj, Romania

  • Targu Mures Clinical County Emergency Hospital

    Târgu Mureş, Mureș County, Romania

  • National University Hospital

    Singapore, Singapore

  • Pusan National University Hospital

    Busan, South Korea

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.